In the case of the MiniSim, passing results were obtained after shortening the length of the animal experiment. This resulted in an increased risk and reduction in quality of the results. I think some ethical points should also be considered and it should be kept in mind that these devices are going into people’s bodies. If shortening the time of the experiments is proved to not increase the overall risk of the product then maybe it’s worth it. But in terms of this mini-sim, a longer experiment could help detect potential side effects that are not seen within the 4 weeks. The take away message for me is that while these companies are trying to reduce costs and cutting down time, their main concern should be the safety of their customer, and extending the deadline for a crucial experiment should be a no brainer if it’s needed, regardless of what management originally demands.